Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.24.2.u1
ACCRUED EXPENSES
 6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following (in thousands):

 

 

 

June 30,
2024

 

 

December 31,
2023

 

 

 

 

 

 

 

 

Accrued pre-clinical and clinical costs

 

$

1,174

 

 

$

1,449

 

Accrued product development costs

 

 

737

 

 

 

745

 

Accrued license costs

 

 

4,125

 

 

 

4,825

 

Accrued compensation

 

 

2,297

 

 

 

2,326

 

Accrued administrative costs

 

 

625

 

 

 

343

 

Accrued interest

 

 

1,530

 

 

 

1,342

 

Total

 

$

10,488

 

 

$

11,030

 

 

For the three and six months ended June 30, 2024 and 2023, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.